Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report)'s share price was up 3.6% during mid-day trading on Thursday . The company traded as high as $7.17 and last traded at $7.11. Approximately 77,368 shares traded hands during trading, a decline of 2% from the average daily volume of 79,007 shares. The stock had previously closed at $6.86.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "buy" rating and issued a $60.00 price objective on shares of Precision BioSciences in a report on Thursday, August 22nd.
Check Out Our Latest Stock Report on Precision BioSciences
Precision BioSciences Trading Up 2.5 %
The company has a market capitalization of $55.91 million, a P/E ratio of 121.52 and a beta of 1.71. The company has a debt-to-equity ratio of 0.34, a quick ratio of 9.22 and a current ratio of 9.22. The stock has a fifty day moving average of $8.40 and a 200 day moving average of $9.71.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC grew its position in Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) by 40.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 65,974 shares of the company's stock after purchasing an additional 19,088 shares during the quarter. Geode Capital Management LLC owned approximately 0.86% of Precision BioSciences worth $591,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 37.99% of the stock is currently owned by hedge funds and other institutional investors.
Precision BioSciences Company Profile
(
Get Free Report)
Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
Read More
Before you consider Precision BioSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Precision BioSciences wasn't on the list.
While Precision BioSciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
